Pompe disease results from the deficiency of the lysosomal enzyme acid a-glucosidase (GAA), leading to accumulated glycogen in the heart and the skeletal muscles, which causes cardiomyopathy and muscle weakness. In this study, we tested the feasibility of gene therapy for Pompe disease using a lentivirus vector (LV). Newborn GAA knockout mice were treated with intravenous injection of LV encoding human GAA (hGAA) through the facial superficial temporal vein. The transgene expression in the tissues was analyzed up to 24 weeks after treatment. Our results showed that the recombinant LV was efficient not only in increasing the GAA activity in tissues but also in decreasing their glycogen content. The examination of histological sections showed clearence of the glycogen storage in skeletal and cardiac muscles 16 and 24 weeks after a single vector injection. Levels of expressed hGAA could be detected in serum of treated animals until 24 weeks. No significant immune reaction to transgene was detected in most treated animals. Therefore, we show that LV-mediated delivery system was effective in correcting the biochemical abnormalities and that this gene transfer system might be suitable for further studies on delivering GAA to Pompe disease mouse models.
Introduction
Pompe disease, also referred to as glycogen storage disease type II (GSDII) and acid maltase deficiency, is an autosomal recessive disorder caused by the deficient activity of the lysosomal enzyme acid a-glucosidase (GAA), which leads to the progressive intralysosomal glycogen accumulation in multiple tissues and cell types, with the cardiac, skeletal and smooth muscle cells being the most seriously affected. The disease presents as a spectrum of features in which symptoms can manifest at any age. Patients with the infantile-onset form of the disease present hypotonia, generalized muscle weakness and hypertrophic cardiomyopathy in the first few months of life, followed by death from cardiorespiratory failure or respiratory infection usually by the age of 1 year. Juvenile and adult-onset diseases (late-onset forms) are characterized by a lack of severe cardiac involvement and a less short-term prognosis. [1] [2] [3] [4] [5] The current available treatment is the enzyme replacement therapy (ERT) with recombinant human acid GAA (Myozyme, Genzyme Corporation, Cambridge, MA, USA); however, the incomplete skeletal muscle clearance of the accumulated substrate in some patients still remains a considerable concern.
1,6-8 Recombinant adenovirus and adeno-associated virus vector-mediated strategy increased GAA activity in serum and tissues and cleared the glycogen deposits in affected muscles after systemic delivery of the recombinant viral vectors encoding GAA; 9, 10 however, the decrease in the treatment efficacy due to anti-GAA antibody formation was reported. 9, 11 To overcome this hurdle, the use of tissuespecific promoters [12] [13] [14] [15] and the neonatal gene transfer have been described. 16, 17 Lentiviral vectors (LV) have been under active consideration for gene therapy for lysosomal storage diseases. 18 Kobayashi et al. 19 reported sustained expression of enzymatically active iduronidase in multiple organs in the murine model of mucopolysaccharidosis type I after neonatal intravenous administration of LV. Richard et al. 20 reported that the use of LV-mediated system was able to provide sufficient GAA expression in the recipient myoblasts in vitro and was able to clear lysosomal glycogen storage. Therefore, we describe here the in vivo effects after a single injection of a third-generation self-inactivating LV encoding the human GAA (hGAA) gene under the control of the ubiquitous cytomegalovirus (CMV) promoter. In an attempt to prevent an immune response, LVs were injected intravenously during the newborn period of Pompe knockout (KO) mice.
Results

Development and production of LV expressing GAA
The third-generation self-inactivating LV-CMV-GAA was produced by a four plasmid packaging system transient transfection of 293T cells using the CMV promoter from the previously described pre-vector plasmid, pRRLsin.hCMV-MCS(R)-Deco-cppt, to drive the expression of the hGAA cDNA and concentrated by ultracentrifugation to titers in the range of 4.5 Â 10 8 -1.3 Â 10 9 infectious units (IU) ml À1 , as estimated by p24 value quantification. 21, 22 First, we evaluated the transgene expression in vitro by transduction of 293T with a single exposure to the LV-CMV-GAA in serial dilutions. Tissue culture plates were coated with 1 Â 10 6 293T cells and exposed to LV-CMV-GAA at dilutions of 1:2, 1:5 and 1:10. On the next day, the vector-containing medium was replaced with fresh medium, and 48 h later, the cells were collected and analyzed by measuring the GAA enzyme activity using fluorimetric assay. The average of GAA level in transduced cells showed a dose-dependent increase in enzyme activity (data not shown).
Sustained high-level expression of GAA in plasma after newborn treatment Following 4 weeks of treatment, serum samples of treated mice were tested for the presence of hGAA every other week using enzyme-linked immunosorbent assay (ELISA), 14 and circulating hGAA could be detected at all time points until 24 weeks after treatment. We also measured the level of GAA in three normal human serum samples that served as controls. The mean levels of hGAA in serum after 4 weeks until 12 weeks of treatment were above the levels of human controls, and thereafter, the GAA level was sustained up to 24 weeks (Figure 1 ).
Increase in GAA activity and reduction of glycogen storage in various tissues of mice treated with LV-CMV-GAA vector
The GAA activity in the hearts of the treated group was about 2-16 times higher than the wild-type group (Table 1) . In diaphragm, the difference between Gaa À/À -treated and Gaa À/À -untreated group was statistically significant at 12 and 24 weeks after treatment and, although we could not show any statistically significant difference between the treated and the untreated group at 4 and 16 weeks after treatment, at these ages, the GAA activity in treated mice was above the widely proposed therapeutic threshold of 20%. 1, 2 In the liver, there was also a statistically significant increase in GAA activity after newborn injection, which was sustained through 24 weeks ranging from 28 to 96% of wild-type group values. In the quadriceps, there was an increase ranging from 2 to 5 times that of enzyme activity in the Gaa À/À -treated group in comparison with Gaa À/À -untreated group, and the increased enzyme activity was sustained during all the 24 weeks of the duration of the study, although statistically significant difference could be detected only at 4 and 12 weeks after treatment (Table 1) .
Glycogen content presented a significant decrease at all time points tested in the heart, with the exception of 16 weeks, when it presented a decrease of 23% in comparison with Gaa À/À -untreated group (Table 2) . In the quadriceps, there was a significant decrease in glycogen storage after 24 weeks of treatment and at the other time points tested, the percentage of storage decrease ranged from 6.7 to 21% (Table 2) . Although decreased, the levels of glycogen in tissues after treatment remained higher than the untreated normal controls (Table 2) .
To determine the distribution of the transgene, the heart, diaphragm, liver and quadriceps were analyzed by PCR, in which the bands corresponding to the amplified LV sequence (142 kb) could be detected in all four tissues tested at 4 weeks of age. After this time point, bands could be detected only in the heart and liver until 24 weeks of treatment (data not shown). When we performed the quantitative PCR, we noticed that at all time points tested, only the heart and liver presented transduced cells with an experimental variation of the percentage of transduction tending to decrease during the observation period, whereas in the diaphragm and quadriceps, the percentage of transduced cells remained below the detection limit of the technique (Table 3) . Of note, no vector genomes could be detected by end point PCR and quantitative PCR, in the gonads of both male and female animals treated with LV-CMV-GAA (data not shown).
Restoration of GAA activity decreases periodic acidSchiff-positive granules in the quadriceps and heart
In an attempt to evaluate the efficacy of the LV-CMV-GAA in clearing the glycogen storage long-term after Neonatal lentivirus gene transfer for murine GSDII SO Kyosen et al Mann-Whitney unpaired test comparing treated versus untreated groups: *Po0.05, **Po0.01, ***Po0.001 and NS, P40.05. (Table 4) , and a decrease in the percentage of muscle fibers containing PAS-reactive granules in the heart and quadriceps (Table 4) .
Although the number of PAS-reactive granules in the pathological sections of treated animals was decreased, it still remained higher than that in the C57BL/6 mice. Furthermore, there was a discrepancy in the pathological and biochemical glycogen results. Coincidentally, we found that the mice used for pathological analysis had the highest GAA serum activity among the age-matched treated animals, and this variation among treated animals might be due to some technical issue of the neonatal intravenous injection.
Lack of CD4
+ and CD8 + cell infiltration and mild humoral immune response against expressed GAA The cellular immune response was investigated immunohistochemically using CD4
+ and CD8 + -specific antibodies in the heart, liver and quadriceps of mice after 4 weeks of treatment and there was no infiltration of CD4 + and CD8 + cells (data not shown). Of all the 43 treated mice, IgG antibodies could be detected in 3 mice at different time points. In these mice, serum hGAA levels could not be detected by ELISA (data not shown), the percentage of transduction in the liver and heart cells was lower in the seropositive mice in comparison with the seronegative ones ( Figure 4a ) and there was a decrease in GAA activity in both the organs in the seropositive mice (Figure 4b ).
Discussion
The ERT with recombinant hGAA is the only approved therapy for Pompe disease. 6, 7 However, to achieve clearance of glycogen in skeletal muscle, high enzyme level is required, which can also elicit antibody responses. 7, 23 The impaired efficacy of ERT for other lysosomal storage diseases 24 and of gene therapy for glycogen storage disease type II 25 due to neutralizing antibodies was already described, and efforts have been made to render immunotolerance to hGAA therapeutics. 12, 23, 26, 27 Thus, to overcome this hurdle, neonatal gene transfer can be a useful therapeutic approach for this and other related lysosomal storage diseases. The age of killing and the number of newborn treated mice are as follows: 4 weeks (n ¼ 6), 8 weeks (n ¼ 10), 12 weeks (n ¼ 7), 16 weeks (n ¼ 11) and 24 weeks (n ¼ 9). 
19,28-30
In this study, the LV injection during neonatal period proved to be a feasible treatment approach for murine Pompe disease once we achieved a long-term stable transgene expression in serum, with elicitation of a mild humoral immune response. Mah et al. 17 reported physiological improvement of the cardiorespiratory function after neonatal gene transfer of adeno-associated virus (AAV) vector, with the elicitation of anti-hGAA antibody formation that was highest at 11 weeks postinjection followed by a drop after 15 weeks and reduction to background levels by 31 weeks posttreatment. We also attempted to evaluate the physiological cardiac function of mice aged 24 weeks using echocardiography, and found no difference in the echocardiographic parameters between the Gaa À/À -untreated mice and C57BL/6-untreated mice (data not shown).
The use of AAV vectors for gene therapy for Pompe disease has been described by several authors with variable responses.
9,12-17 Sun et al. 15 reported long-term correction of multiple muscles in GAA-KO mice on administrating AAV vector containing a muscle-specific regulatory cassette, and Ziegler et al.
14 achieved biochemical and motor function correction of presymptomatic and symptomatic GAA-KO mice using AAV serotype 8. However, the translation of the previous results to clinical trials using AAV vectors has to overcome some hurdles, as it was reported that in humans, in a clinical trial for hemophilia B, T-cellmediated immunity to AAV capsid antigens caused destruction of AAV2-transduced hepatocytes, impairing the long-lasting expression of the transgene. 31 The LVs present some advantages when compared with other vector systems, such as efficient integration in the host genome, absence of viral genes from the genetic information transferred to the recipient, ability to infect nondividing cells and lack of pre-existing immunity in the recipient. 18, 32 Furthermore, in a phase I open-label nonrandomized clinical trial for human immunodeficiency virus (HIV), sustained gene transfer with improvement of immune functions without evidence of insertional mutagenesis after 21-36 months was observed. 33 The LV system had been used as a therapeutic approach for gene therapy for MPS I, 19, 34 MPS III 35 and Fabry disease. 36 Recently, it was reported that a LV-mediated system was able to provide sufficient GAA expression in recipient myoblasts in vitro 20 and induce immunotolerance in mice that underwent ERT. 37 As a first attempt using a LV, we decided to place the gene expression under the control of an ubiquitous CMV promoter. Our results showed that the provirus DNA sequence could be detected in the heart and liver, whereas it was not possible to detect any viral sequence in the diaphragm or quadriceps. This result, in addition to high serum levels of hGAA, led us to conclude that the heart and liver worked as a depot of hGAA, and that the effect in distal organs was a result of cross-correction. We also noticed that the decrease in the percentage of transduced cells in the liver and heart was concomitant with the decrease in the GAA activity in both tissues. Taken together, it is more likely that there was a loss of transduced cells than an effect of the CMV promoter shutdown. 
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We could detect a significant decrease in the glycogen content of the heart of treated mice at all time points tested, with an exception of 16 weeks after treatment, and we also detected a slight decrease in the glycogen content in the quadriceps of the treated mice. In both tissues, the biochemical analysis of glycogen levels remained higher than that in untreated normal animals, whereas in the pathological analysis, there was a significant decrease in the PAS-reactive granules.
Although there was high expression of GAA in the heart, sometimes reaching supraphysiological levels, the glycogen clearance was not complete. The reason for this discrepancy is still not clear, and one possible explanation is that the autophagy build-up in this disease [39] [40] [41] [42] impairs the glycogen clearance in muscle fibers, because the circulating enzyme, which was endocytosed, became trapped in autophagosomes, late endosomes and intermediate autophagosomes, resulting in impaired targeting of the expressed enzyme to the lysosome, 43 leading to partial correction of glycogen storage. Another possibility is that, as in previous studies using AAV vector the glycogen clearance in the heart was complete and in our study it was only partial, 14, 15, 44 we speculated that maybe some cardiac cells are refractory to LV infection, although this statement needs further investigation.
In this study, we also detected a difference in response to treatment between the heart muscle fiber and skeletal muscle fiber, and previous authors also reported the increased resistance to glycogen clearance by the skeletal muscle when compared with cardiac muscle. 25, 45, 46 Until now, the reason why the skeletal muscle is more refractory than the heart to enzyme therapy is unclear, but may be related to the larger mass of skeletal tissue, and perhaps also to the differences in the relative accessibility of the circulating enzyme to different tissues. 47 The skeletal muscles also purportedly have less cation-independent M6P receptor that is essential for cellular uptake of the lysosomal enzyme. 47 West et al., 48 taking advantage of the immature immune response of newborns who do not yet produce antibodies to T-cell-independent antigens including the major blood-group antigens, reported successful cardiac transplantation in ABO-incompatible infants aged between 4 h and 14 months. Of all the 10 infants studied, the overall survival was 80%, and in only 1 infant was a mild humoral rejection noted in the autopsy. 48 Chien et al., 49 in a large-scale study of the Taiwanese population, showed that the newborn screening for Pompe disease allowed earlier diagnosis, and thus, earlier start of treatment. Taken together, these previous reports allow us to speculate that when gene therapy for Pompe disease turns to clinical practice, the neonatal gene transfer of the LV might be considered as a feasible treatment approach for patients diagnosed by newborn screening.
Reduced immune responses in newborn mice seem to be due to reduced production of cytokines, reduced levels of co-stimulatory molecules and reduced maturity and responsiveness of antigen-presenting cells. 28 However, it is not enough to completely avoid antibody formation against autologous protein. Madoiwa et al. 50 have reported that administration of human factor VII within 24-30 h after birth resulted in tolerance after subsequent protein injections to adults in B90% of mice. On the basis of the difference of percentage of the Table 4 Histological analysis of percentage of PAS-reactive muscle fibers in the heart and quadricep samples of treated and untreated mice at 16 weeks and 24 weeks of age, and sizes of PASreactive granules in the liver samples of treated and untreated mice 16 weeks and 24 weeks of age c n represents number of PAS-reactive granules counted in one treated and two untreated mice at 24 weeks of age.
Neonatal lentivirus gene transfer for murine GSDII SO Kyosen et al transduced cells between the seropositive and seronegative groups, we can speculate that in the seropositive group, the injected dose of LV-CMV-GAA was, for some technical reason, lower than the seronegative group and elicited a humoral immune response, which caused the decreased GAA activity. We have shown that IgG antibodies formed during ERT administered to Fabry disease patients exert an inhibitory effect on a-Gal A enzyme activity in Fabry fibroblast cells and tissues from Fabry mice. 24 Another possible explanation is that, in the three seropositive mice, both cytotoxic T-lymphocyte and humoral immune response were elicited, and the cytotoxic response was responsible for the decrease in the percentage of transduced cells in seropositive mice. However, in all treated mice, the measurement of serum alanine aminotransferase, which was used as a screening for cytotoxic liver reaction, did not show an increase in comparison with untreated mice and the liver and heart sections at 4 weeks after treatment did not show CD4 + and CD8 + cell infiltration. In conclusion, we report here the development of a LV expressing the GAA enzyme using the CMV promoter, which was injected during the neonatal period to Gaa À/À mice, and achieved stable expression and reduction of glycogen storage with elicitation of minimal immune response. Further studies regarding one of the major concerns in gene therapy, which is the risk of mutagenesis and oncogenesis, 51 are still needed.
Materials and methods
Generation of LV-CMV-GAA
The 3.7 kb fragment of the hGAA cDNA extracted using the EcoRI restriction enzyme from the pKW59 plasmid (courtesy of Dr YT Chen, Academia Sinica, Taipei, Taiwan) and the 6.7 kb fragment from the pRRL-sinhCMV-MCS(R)-Deco-cPPT pre-vector (kindly provided by Dr N Kasahara, University of California, Los Angeles, USA), 52 were purified from agarose gel using the Sephaglass Band Prep Kit (Amersham Biosciences, Litle Chalfont, UK) and then submitted to random ligation using the Blunting and Ligation Kit (Toyobo Co., Osaka, Japan). This placed the expression of GAA under the transcriptional control of the human CMV promoter. Large-scale production of recombinant LVs encoding GAA was performed by transient four plasmid cotransfection of 293T followed by purification by ultracentrifugation, as previously described. 21 The titer was determined by assessing viral p24 antigen concentration by ELISA (Cell Biolabs Inc., San Diego, CA, USA) and expressed as infective units (IU) per ml.
Animal procedures
GAA-KO mice (a courtesy from Dr N Raben, NIH, Bethesda, MD, USA) 53 and wild-type C57BL/6 mice (Sankyo Labs, Tokyo, Japan) were housed in small groups with free access to food and water. All studies were approved by the Institutional Animal Care Committee. Gene transfer was performed by intravenous administration through the superficial temporal vein within the first 48 h of life. 54 At specific time points, animals were killed by cervical dislocation under anesthesia, organs were harvested and either processed with fixative or snap-frozen and stored at À80 1C until they were ready to be analyzed.
Determination of serum and tissue levels of GAA activity and tissue glycogen content Blood samples from animals were obtained by retroorbital bleeding after 4, 6, 8, 10, 12, 14, 16, 18, 20, 22 and 24 of newborn treatment and the serum hGAA level was assayed by ELISA, as previously described.
14 For the GAA activity assay in tissues and glycogen content determination, frozen tissues were homogenized in sterile water at a concentration of B100 mg ml À1 and analyzed 4, 8, 12, 16 and 24 weeks after treatment. Tissue GAA levels were determined by enzymatic activity assay using the fluorogenic substrate 4-methylumbelliferyl À1 per mg protein the in heart and liver. Results represent mean ± s.e.m.: GAA activity in heart of seropositive mice aged 16 weeks ¼ 2.6 ± 0.2 (n ¼ 2) and GAA activity in heart of seronegative mice aged 16 weeks ¼ 164.7 ± 58.4 (n ¼ 9); GAA activity in heart of seropositive mice aged 24 weeks ¼ 28.09 (n ¼ 1) and GAA activity in heart of seronegative mice aged 24 weeks ¼ 374±74.8 (n ¼ 8). GAA activity in liver of seropositive mice aged 16 weeks ¼ 5.6±0.6 (n ¼ 2) and GAA activity in liver of seronegative mice aged 16 weeks ¼ 74.3±23.4 (n ¼ 9); GAA activity in liver of seropositive mice aged 24 weeks ¼ 6.57 (n ¼ 1) and GAA activity in liver of seronegative mice aged 24 weeks ¼ 81.6 ± 29.3 (n ¼ 8).
Neonatal lentivirus gene transfer for murine GSDII SO Kyosen et al a-D-glucopyranoside (Sigma-Aldrich, St Louis, MO, USA), as previously described. 55 To assay the glycogen content, mice were fastened for 8 h to decrease the intracytoplasmatic glycogen and then tissue homogenates were digested with 0.54 mg ml À1 a-amyloglucosidase (SigmaAldrich) in 25 mM potassium acetate buffer (pH 5.5). Using the Amplex Red Glucose/Glucose Oxidase assay kit (Invitrogen, Carlsbad, CA, USA), the released glucose in the test samples and the levels of endogenous glucose from undigested samples were quantified. Glycogen levels were determined by subtracting the glucose levels in the undigested samples from the digested samples. Bovine liver glycogen (Sigma-Aldrich) was used as a reference standard. ) and then serial dilutions of serum were added to them. Bound antibodies were detected using goat anti-mouse IgG (H+L) (Kirkergaard & Perry Laboratories Inc, Gaithersburg, MD, USA). After washing, the peroxidase activity was detected by 3,3 0 ,5,5 0 -tetramethylbenzidine (Promega Co., Madison, WI, USA) and the absorbance was measured at 450 nm using ARVO MX/Light Wallac 1420 Multilabel/Luminescence Counter (Perkin Elmer Co., Japan). Titers were defined as the reciprocal of the highest dilution of serum that produced an optical density at 450 nm equal or higher than the double of naive absorbance in the same dilution.
PCR and quantitative PCR analysis of LV cDNA
Genomic DNA from tissues was purified using a DNeasy Tissue Kit (Qiagen, Valencia, CA, USA) and PCR was performed in a 50 ml reaction mixture containing 100 ng of genomic DNA. Quantification of vector copy number in 25 ml reaction mixture containing 100 ng of genomic DNA was performed using the TaqMan Universal PCR Master Mix (Applied Biosystems, Foster City, CA, USA), as previously described. 21 Amplifications were carried out in an ABI PRISM 7300 sequence detector (Perkin Elmer Co.). To calculate percentage of transduced cells in tissue samples, a reference curve was prepared by amplifying serial dilutions of LV-CMV-GAA plasmid in a background of genomic DNA from nontreated mice, and the Ct values were plotted against the input plasmid generating a standard reference curve.
Histopathology
Deeply anesthetized mice were perfused through the heart with 2.5% glutaraldehyde (GA, Wako Co., Osaka, Japan) and 0.1 M phosphate-buffered saline (PBS, pH 7.4). The diaphragm, heart, liver and quadriceps were removed and immersion-fixed in 2.5% glutaraldehyde and 0.1 M PBS (pH 7.4) for 2 h at 4 1C, followed by treatment with 1% osmium tetroxide in 0.1 M PBS (pH 7.4) for 2 h at 4 1C. Tissues were dehydrated and polymerized with Epon 812 resin (TAAB, England, UK). Slides of 1 mm thickness were hydrated in deionized water for 5 min, followed by 5-min incubation in 0.5% periodic acid at room temperature (RT). After rinsing in tap water, slides were incubated in Schiff's reagent at RT for 10 min. After drying completely at 60 1C in the oven, the slides were coverslipped using Epon 812 resin.
The numbers of PAS-reactive granules per 0.01 mm 2 were counted in the heart, diaphragm, liver and quadriceps. The mean numbers of granules per 0.01 mm 2 were obtained from counts of 10 fields in each tissue per mouse. The sizes (mm 2 ) of PAS-reactive granules in the liver of the Pompe mice with/without treatment were measured and calculated using Photoshop CS3 extended (ver. 10.0.1, Adobe Systems Incorporation, San Jose, CA, USA) software. The number of muscle fibers with PAS-reactive granules per 100 muscle fibers was counted in the heart and quadriceps.
CD4
+ and CD8 + lymphocyte immunodetection
Frozen sections (10 mm) of the heart, liver and quadriceps were air dried for 30 min, fixed in ice-cold methanol for 10 min and washed in 0.01 M PBS (pH 0.4-7.6). After blocking endogenous peroxidase with 0.3% H 2 O 2 in methanol for 30 min at RT, slides were incubated with anti-CD4 + (Abcam, Cambridge, UK) or anti-CD8 + (RELIATech GmbH, Germany) antibody in 10% normal goat serum, 5% bovine serum albumin, 0.01% Tween 20 and 0.01 M PBS buffer overnight at 4 1C. Biotinylated goat anti-rat antibody (Vector Labs, Burlingame, CA, USA) in PBS were applied for 1 h at RT and sections were serially stained with avidin-biotin procedures using ABC kit (Vector Labs) and 3,3
0 -diaminobentizine as a chromogen. Counterstaining for cell nuclei was performed with Mayer's hematoxylin.
Statistical analyses
Statistical analyses were performed using Prism 5.0 (GraphPad, San Diego, CA, USA) and JMP software (ver. 7.0.2, SAS Institute Inc, NC, USA) software. The significance of the differences between the GAA enzyme activity and glycogen content in tissues of Gaa À/À -treated and untreated group was assessed by MannWhitney nonparametric test. A level of Po0.05 was accepted as statistically significant. The significance of the differences among the mice for the mean numbers of granules in each organ, the mean sizes of PAS-positive and PAS-negative granules in the liver and the ratio of muscle fibers with PAS-reactive granules was assessed by Tukey-Kramer's HSD test, student's t-test, or w 2 -test. A level of Po0.05 was accepted as statistically significant.
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